Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Plus Therapeutics Inc banner

Plus Therapeutics Inc
XBER:XMPA

Watchlist Manager
Plus Therapeutics Inc Logo
Plus Therapeutics Inc
XBER:XMPA
Watchlist
Price: 0.206 EUR -21.37% Market Closed
Market Cap: €3.2m
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Gross Profit
Loading...
Operating Income
Loading...
Pre-Tax Income
Loading...
Net Income
Loading...

Wall St Price Targets

XMPA Price Targets Summary
Plus Therapeutics Inc

Wall Street analysts forecast XMPA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XMPA is 1.901 EUR with a low forecast of 0.594 EUR and a high forecast of 3.347 EUR.

XMPA Lowest Forecast
0.594 EUR
189% Upside
XMPA Average Forecast
1.901 EUR
823% Upside
XMPA Highest Forecast
3.347 EUR
1 525% Upside
Lowest Forecast
Price Target
0.594 EUR
189% Upside
Average Forecast
Price Target
1.901 EUR
823% Upside
Highest Forecast
Price Target
3.347 EUR
1 525% Upside
Plus Therapeutics Inc Competitors:
Price Targets
TTD
Trade Desk Inc
48% Upside
NYXH
Nyxoah SA
538% Upside
FLEX
Flex Ltd
8% Upside
NWSA
News Corp
41% Upside
TTD
Trade Desk Inc
48% Upside
NYXH
Nyxoah SA
538% Upside
FLEX
Flex Ltd
8% Upside
NWSA
News Corp
41% Upside

Revenue
Forecast

-5% / Year
Past Growth
107% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
-5% / Year
Past Growth
107% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been -5%. The projected CAGR for the next 3 years is 107%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

What are analyst estimates?

See Also

Summary
XMPA intrinsic value, competitors valuation, and company profile.
DCF Valuation
XMPA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
XMPA stock valuation using valuation multiples.
Wall St Estimates
XMPA price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
XMPA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Plus Therapeutics Inc listings:
NASDAQ • USD
PSTV
 F • EUR
XMPA
 NASDAQ • USD
CYTX
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is XMPA's stock price target?
Price Target
1.901 EUR

According to Wall Street analysts, the average 1-year price target for XMPA is 1.901 EUR with a low forecast of 0.594 EUR and a high forecast of 3.347 EUR.

What is the Revenue forecast for Plus Therapeutics Inc?
Projected CAGR
107%

Over the last 14 years, the compound annual growth rate for Revenue has been -5%. The projected CAGR for the next 3 years is 107%.

Back to Top
ALPHA SPREAD
Follow us
Join 343,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett